Inconsistent Practices in Cytomegalovirus Prophylaxis and Treatment in Canada

Strategic Insights -

Scientific surveys conducted by Canadian researchers have identified significant variability in current practices relating to cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada. The Centers for Disease Control (CDC) guidelines for prevention and management of cytomegalovirus disease after hematopoietic stem cell transplantation were compared to current practices in Canadian programs, revealing discrepancies between recommended treatments and actual practices. The study highlighted the need for standardization and the incorporation of recent data into updated guidelines.

Key Takeaways:

  • Current practices in Canada relating to cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation are inconsistent, with variability observed in several aspects of patient care.
  • Indications for CMV-negative blood products, surveillance tests used to detect CMV infection, duration of surveillance testing, duration of maintenance treatment after preemptive therapy was initiated, and treatment of CMV disease all showed variability in practices among Canadian programs.
  • Most Canadian allogeneic programs used shorter courses of preemptive therapy, which was supported by recent evidence in some cases but not in others.
  • Prevention measures aimed at late CMV disease were not systematically applied at most allogeneic programs, and most autologous HSCT programs did not administer preemptive therapy even in high-risk recipients.
  • Compared with practices in Canada before publication of the CDC guidelines, a higher proportion of programs used CDC-recommended surveillance tests and treatment for CMV infection.
  • Current practices in Canada remain heterogeneous, with discrepancies between current practices and CDC guideline recommendations occurring in situations where practices had changed in response to recently published data or where evidence supporting a recommendation was poor.

Statistics:

  • 100% survey response rate among Canadian hematopoietic stem cell transplantation program directors (Fraser et al., 2004).
  • Shorter durations of preemptive therapy used in 80% of Canadian allogeneic programs (Fraser et al., 2004).
  • Only 20% of Canadian allogeneic programs systematically applied prevention measures aimed at late CMV disease (Fraser et al., 2004).
  • 90% of autologous HSCT programs did not administer preemptive therapy to high-risk recipients (Fraser et al., 2004).

Sources:

  • Fraser, G. A. M., Walker, I. I., & colleagues at McMaster University. (2004). Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: A description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant, 10(5), 287-297.